Adicet Bio, Inc. (ACET) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company is a "smaller reporting company" and a "non-accelerated filer." Its lead product candidate, prula-cel, is in Phase 1 trials for autoimmune indications including lupus nephritis (LN) and systemic lupus erythematosus (SLE). A second candidate, ADI-212, targets prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer (mCRPC).
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(21.4) million | $(31.2) million | $(41.6) million | $(59.4) million |
| Net Loss Per Share | $(1.99) | $(5.48) | $(3.87) | $(10.40) |
| Operating Expenses | $22.3 million | $32.4 million | $43.9 million | $62.3 million |
| Cash & Equivalents | $33.1 million (as of June 30, 2026) | |||
| Short-Term Investments | ||||
| Total Liquidity | $118.2 million (Cash + Investments) | |||
| Accumulated Deficit | $(656.3) million | |||
| Debt | No term loan principal outstanding; minimal finance lease liabilities. |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 31% in Q2 2026 compared to Q2 2025 ($22.3M vs. $32.4M). This was driven by a 35% reduction in R&D expenses and a 3% reduction in G&A expenses.
- R&D Drivers: The decrease in R&D was primarily due to lower Contract Research Organization (CRO) expenses ($4.0M decrease) due to no new patient enrollment, lower payroll/personnel costs ($2.8M decrease) due to reduced headcount, and reduced facility-related expenses.
- Improved Loss Profile: Net loss improved significantly, decreasing by 32% in Q2 2026 compared to the same period in 2025.
- Capital Structure: The company completed a registered direct offering in October 2025 raising approximately $74.8 million. In April 2026, the company exchanged 250,000 shares of common stock for a pre-funded warrant.
Guidance, Outlook, and Risks
- Clinical Outlook:
- prula-cel: The company plans to provide a comprehensive clinical update in Q3 2026 for LN and SLE patients. A potential pivotal trial design is being advanced, with startup activities anticipated to commence in the second half of 2026. Data for systemic sclerosis (SSc) is expected in H2 2026.
- ADI-212: The company expects to submit a regulatory filing (IND) for mCRPC in Q3 2026, with patient enrollment anticipated to start in Q4 2026.
- Liquidity: Management expects current cash, cash equivalents, and short-term investments ($118.2 million) to fund operations for at least the next 12 months. No revenue is expected until regulatory approval is obtained.
- Management Changes: On August 3, 2026, Dr. Julie Maltzman resigned as Chief Medical Officer. Dr. Lloyd Klickstein was appointed Interim Chief Medical Officer effective August 3, 2026.
- Key Risks:
- Regulatory & Clinical: Failure of clinical trials to demonstrate safety/efficacy; delays in regulatory approvals; reliance on novel gamma delta T cell technology.
- Financial: Need for substantial additional financing; history of significant losses; potential dilution from future equity offerings.
- Operational: Dependence on third-party manufacturers (CDMOs); reliance on key personnel; geopolitical risks affecting operations in China.
Investor Verification Checklist
- Verify the timeline and data cut-off for the upcoming Q3 2026 clinical update on prula-cel in LN and SLE.
- Confirm the status of the IND submission for ADI-212 in Q3 2026 and enrollment plans for Q4 2026.
- Monitor cash burn rate relative to the $118.2 million liquidity position to assess runway beyond the stated 12-month period.
- Review the impact of the recent Chief Medical Officer transition on clinical trial execution.
- Assess the status of the China operations (Shanghai Adicet) and any regulatory hurdles related to the Foreign Investment Law or data transfer restrictions.